Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
111.9 EUR | -0.99% |
|
+2.32% | +24.72% |
Jul. 12 | China approves CSPC Pharma's RSV vaccine for clinical trials | RE |
Jul. 10 | Flagship Pioneering Raises $3.6B for 'New Wave' of Health, AI Innovation | MT |
Evolution of the average Target Price on Moderna, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
![Consensus](/images/consensus_flch.gif)
Consensus detail
Consensus revision (last 18 months)
Analysts covering Moderna, Inc.
Argus | |
JPMorgan Chase | |
Oppenheimer | |
Jefferies & Co. | |
RBC Capital Markets | |
Evercore ISI | |
Deutsche Bank Securities | |
UBS | |
Goldman Sachs | |
Leerink Partners | |
Morgan Stanley | |
Redburn | |
HSBC | |
Canaccord Genuity | |
RBC | Luca Issi |
TD Cowen | |
William Blair & Co. | |
Guggenheim | |
SVB Securities LLC | |
Cowen | |
Chardan Research | |
Piper Sandler | |
SVB Leerink | |
BofA Securities | |
Wolfe Research | |
Barclays | |
Chardan | |
J.P. Morgan Chase |
EPS Revisions
- Stock Market
- Equities
- MRNA Stock
- 0QF Stock
- Consensus Moderna, Inc.